Thioureas (i.e., Hnh-c(=s)-hnh, Wherein Substitution May Be Made For Hydrogen Only) Patents (Class 564/17)
  • Patent number: 8956423
    Abstract: The present invention relates to a method of increasing the chlorine fastness of dyed synthetic polyamide fiber materials, which comprises treating the fiber material after dyeing with an aqueous liquor comprising a thiourea/formaldehyde/bisphenol condensate or a thiourea/polyisocyanate adduct.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: February 17, 2015
    Assignee: Huntsman International LLC
    Inventor: Philippe Ouziel
  • Publication number: 20140259455
    Abstract: The present invention relates to a method of increasing the chlorine fastness of dyed synthetic polyamide fibre materials, which comprises treating the fibre material after dyeing with an aqueous liquor comprising a thiourea/formaldehyde/bisphenol condensate or a thiourea/polyisocyanate adduct.
    Type: Application
    Filed: October 16, 2012
    Publication date: September 18, 2014
    Applicant: Huntsman International LLC
    Inventor: Philippe Ouziel
  • Patent number: 8629299
    Abstract: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in the preparation of the [18F]-labelled prosthetic groups. [18F]-labelled compounds useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET) are also provided.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: January 14, 2014
    Assignee: Hammersmith Imanet Limited
    Inventors: Erik Arstad, Matthias Eberhard Glaser
  • Patent number: 8536226
    Abstract: The present invention is directed to the use of a compound of formula (I) or pharmaceutically acceptable salt thereof, for the treatment of disorders mediated by the melanocortin-5 receptor, particularly dermatological disorders; and further directed to pharmaceutical compositions containing the compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: September 17, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Magdalena Eisinger, Fa Zhang
  • Patent number: 8445721
    Abstract: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in the preparation of the [18F]-labelled prosthetic groups. [18F]-labelled compounds useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET) are also provided.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: May 21, 2013
    Assignee: Hammersmith Imanet Limited
    Inventors: Erik Arstad, Matthias Eberhard Glaser
  • Patent number: 8334405
    Abstract: Chiral thioureas are effective catalysts for the borane reduction of prochiral ketones to optically active alcohols. A prochiral ketone may be reduced to an optically active alcohol in the presence of a substantially sub-stoichiometric amount of chiral thiourea. The asymmetric thiourea compound of the present invention may be produced according to a production method described herein.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: December 18, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Derun Li, John R. Falck
  • Patent number: 8148575
    Abstract: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in the preparation of the [18F]-labelled prosthetic groups. [18F]-labelled compounds useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET) are also provided.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: April 3, 2012
    Assignee: Hammersmith Imanet Limited
    Inventors: Erik Arstad, Matthias Eberhard Glaser
  • Patent number: 8043702
    Abstract: A surface-modified, magnetic nanoparticle has one or more multi-dentate ligands bound to a surface of a magnetic nanoparticle. The one or more multi-dentate ligands are bound to the surface of the magnetic nanoparticle through one or more dithiocarbamate groups. The one or more multi-dentate ligands may be a compound of Formula II: R2NCH2[CH2NR?CH2]m[CH2N(CS2?)CH2]q[CH2NHCH2]rCH2NR?2 ??(II) where each R, R?, and R? are independently H, a branched ethyleneimine unit, an unsubstituted or substituted alkyl, an unsubstituted or substituted alkenyl, or an unsubstituted or substituted aryl; and n is an integer from 1 to about 50.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: October 25, 2011
    Assignee: Seoul National University Research & Development Business Foundation (SNU R&DB Foundation)
    Inventor: Jin-Kyu Lee
  • Patent number: 7718385
    Abstract: A rapid screening method for identifying acylfulvenes and acylfulvene analogs with improved chemotherapeutic properties has been developed. The mechanism of toxicity of irofulven, a potentially clinically useful member of the acylfulvene class, has been elucidated and provides guidance for design and testing of a new class of alkylating agents with structures related to irofulven. The role of alkenal/one oxidoreductase (AOR) is shown to be important in cancer cell susceptibility to this class of alkylating agent.
    Type: Grant
    Filed: October 18, 2004
    Date of Patent: May 18, 2010
    Assignee: The Johns Hopkins University
    Inventor: Ryan A. Dick
  • Publication number: 20100048699
    Abstract: A compound of formula I where the substituents have the meanings assigned to them in claim 1, compositions comprising a compound of formula (I) and the use of such compounds and/or compositions controlling insects, acarines, nematodes or molluscs.
    Type: Application
    Filed: June 29, 2007
    Publication date: February 25, 2010
    Applicants: SYNGENTA CROP PROTECTION, INC., SYNGENTA LIMITED
    Inventors: Juergen Harry Schaetzer, Christoph Luthy, William Lutz, Donn Warwick Moseley, Anthony Cornellius O'Sullivan
  • Patent number: 7655817
    Abstract: The present invention relates to a production method of optically active hydrazine compound (IV), which includes reacting azo compound (II) with compound (III) in the presence of optically active compound (I). The present invention also relates to a production method of optically active amine compound (V), which includes producing optically active hydrazine compound (IV) by the above-mentioned method, reacting the optically active hydrazine compound (IV) with a base or an acid to eliminate a protecting group represented by PG, and then subjecting the resulting compound to catalytic reduction or reacting the resulting compound with a zinc powder to reduce a nitrogen-nitrogen bond. wherein X is S or O; C*, C** and C*** are asymmetric carbons, R1 and R2 are lower alkyl groups etc., R4 and R5 may in combination form cyclohexane etc., R3 is aryl group optionally having substituent(s) etc., R6 and R7 are hydrogen atoms etc., R8 is aryl group optionally having substituent(s) etc.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: February 2, 2010
    Assignees: Kyoto University, Sumitomo Chemical Company, Limited
    Inventors: Yoshiji Takemoto, Kazuo Murakami
  • Patent number: 7655695
    Abstract: Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers/tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: February 2, 2010
    Assignee: The Regents of The University of California
    Inventors: Trevor C. McMorris, Michael J. Kelner
  • Patent number: 7632970
    Abstract: The present invention relates to a production method of asymmetric compound (IV) which includes conjugately adding nucleophilic reagent (III) to compound (II) in the presence of asymmetric urea compound (I). The present invention provides a non-metallic asymmetric catalyst capable of realizing a highly stereoselective asymmetric conjugate addition reaction in a high yield, and an advantageous production method of an asymmetric compound by an asymmetric conjugate addition reaction using the asymmetric catalyst.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: December 15, 2009
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Yoshiji Takemoto
  • Publication number: 20090203751
    Abstract: The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder.
    Type: Application
    Filed: August 5, 2008
    Publication date: August 13, 2009
    Inventors: Magdalena Eisinger Eisinger, Louis J. Fitzpatrick, Daniel H. Lee, Kevin Pan, Carlos Plata-Salaman, Allen B. Reitz, Virginia L. Smith-Swintosky, Boyu Zhao
  • Publication number: 20080306147
    Abstract: Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers/tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents.
    Type: Application
    Filed: August 3, 2006
    Publication date: December 11, 2008
    Applicant: The Regents of The University of California Office of Technology Transfer
    Inventors: Trevor C. McMorris, Michael J. Kelner
  • Publication number: 20080207760
    Abstract: The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.
    Type: Application
    Filed: April 11, 2006
    Publication date: August 28, 2008
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventor: Mingjun Huang
  • Patent number: 7326746
    Abstract: Electron donor compounds, suitable for use as adhesives or as components in adhesives, contain a carbon to carbon double bond attached to an aromatic ring and conjugated with the unsaturation in the aromatic ring.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: February 5, 2008
    Inventors: Osama M. Musa, Donald E. Herr, Nikola A. Nikolic
  • Patent number: 7323602
    Abstract: A process for preparing an intermediate compound of formula (II) where n is an integer of from 3 to 14; R1 is haloC1-10alkyl, C1-10alkyl, C2-10alkenyl, C2-10cycloalkyl, carboxyC1-10alkyl, C1-10alkoxycarbonylC1-10alkyl, aryl (such as phenyl), aryl(C1-10)alkyl (such as phenyl(C1-10)alkyl) or di(C1-6alkyl)amino; and R2 is a halo group; the process comprising halogenation of a compound of formula (III) where n and R1 are as defined above. Novel compounds are also described and claimed.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: January 29, 2008
    Assignee: AstraZeneca AB
    Inventors: Kenneth Edwin Herbert Warren, Anne Margaret Lamont Kane
  • Patent number: 7271288
    Abstract: Disclosed is an aromatic compound expressed by the general formula (I), wherein A represents of a fused aromatic hydrocarbon moiety such as triphenylene, X represents a hydrogen-bonding site such as an atomic group containing an amide linkage, Y represents a chain functional group such as an alkyl group having 3 to 18, preferably 10 to 18 carbon atoms, and n represents an integer ranging from 2 to 10. The aromatic compound forms a molecular assembly in which the aromatic rings mutually overlap and exhibits an excellent charge carrier transfer property AX—Y)n.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: September 18, 2007
    Assignee: Kyushu University, National University Corporation
    Inventors: Masayuki Takeuchi, Masato Ikeda, Seiji Shinkai
  • Patent number: 7265136
    Abstract: A compound for use in inducing necrosis in vascular tissue of a tumor in an animal. The compound contains a first moiety which is a cis-stilbene moiety and a second moiety which is an inhibitor of the formation or action of nitric acid. Also, a method for inducing necrosis in vasculature of a tumor in an animal by administering to the animal the compound in an amount effective for inducing the necrosis.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: September 4, 2007
    Assignee: Angiogene Pharmaceuticals Ltd.
    Inventor: Peter David Davis
  • Patent number: 7109375
    Abstract: An additive for an alkaline zinc or zinc alloy electroplating bath medium, the additive comprising a random co-polymer comprising the reaction product of: (i) one or more di-tertiary amines including an amide or thioamide functional group, and (ii) optionally, one or more saturated second di-tertiary amines and/or one or more second di-tertiary amines including an unsaturated moiety, with (iii) one or more saturated or unsaturated linking agents capable of reacting with said di-tertiary amines (i) and (ii), provided that, where all the linking agents are saturated, an unsaturated di-tertiary amine must he present. Preferably, the polymer has the general formula n(2x+2y+zEp)j-.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: September 19, 2006
    Inventors: Roderick Dennis Herdman, Trevor Pearson, Anthony Rowan
  • Patent number: 7053243
    Abstract: 1-(3-methoxybenzyl)-3-substituted thiourea antioxidant compounds and improved lipids compositions which are supplemented with amounts of such antioxidant compounds effective for augmenting oxidative stability of the base lipid are provided. Also provided are methods for enhancing the oxidative stability of a lipid comprising supplementing a base lipid in need of enhanced oxidative stability with at least one 1-(3-methoxybenzyl)-3-substituted thiourea compound of the present invention.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: May 30, 2006
    Assignees: The Fanning Corporation, The United States of America as represented by the Secretary of Agriculture
    Inventors: Thomas P. Abbott, Alan Wohlman
  • Patent number: 6908957
    Abstract: Electron donor compounds, suitable for use as adhesives or as components in adhesives, contain a carbon to carbon double bond attached to an aromatic ring and conjugated with the unsaturation in the aromatic ring.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: June 21, 2005
    Assignee: National Starch and Chemical Investment Holding Corporation
    Inventors: Osama M. Musa, Donald E. Herr, Nikola A. Nikolic
  • Patent number: 6866833
    Abstract: A substituted thiourea having the general formula characterized in that each of R1 and R2 independently comprises an alkyl, alkaryl or aryl group or a substituted derivative thereof, and contains at least one fluorine atom, and in that each of R3 and R4 is selected from the group which consists of H, alkyl, alkaryl and aryl and substituted derivatives thereof, including fluorine-containing derivatives. A method for producing the substituted thiourea is disclosed, and a method for extracting a noble metal such as gold from a matrix by treating the matrix with the substituted thiourea is also disclosed.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: March 15, 2005
    Assignee: University College Cork
    Inventors: Jeremy Denis Glennon, Jane Harris, Stephen John Harris
  • Patent number: 6864380
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: March 8, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Dean A Wacker, John V Duncia, Joseph B Santella, III, Daniel S Gardner
  • Patent number: 6800728
    Abstract: Reagents and methods are provided for crosslinking and immobilizing biomolecules, drugs and synthetic polymers. The reagents possess (i) a thiol or amino reactive group; and (ii) a hydrazino or oxyamino moiety. Conjugates and immobilized biomolecules are also provided.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: October 5, 2004
    Assignee: Solulink Biosciences, Inc.
    Inventor: David A. Schwartz
  • Publication number: 20040116445
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Application
    Filed: November 18, 2003
    Publication date: June 17, 2004
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
  • Publication number: 20040034069
    Abstract: A method for the inhibition of high affinity glycine transporters, compounds that inhibit these transporters; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of disease states in which glycine is involved are disclosed.
    Type: Application
    Filed: August 8, 2003
    Publication date: February 19, 2004
    Inventors: Syed M. Ali, Kurt R. Brunden, Jack B. Jiang
  • Publication number: 20040014758
    Abstract: The present application describes modulators of CCR3 of formula (I): 1
    Type: Application
    Filed: July 3, 2003
    Publication date: January 22, 2004
    Inventors: Dean A. Wacker, John V. Duncia, Joseph B. Santella, Daniel S. Gardner
  • Patent number: 6657082
    Abstract: The present invention relates to an improved process for the preparation of thiourea. The object of the present invention is to provide an improved process for the preparation of Thiourea using Calcium Cyanamide, carbon dioxide and hydrogen sulphide. The process of the present invention comprises passing a mixture of Carbon dioxide and hydrogen sulphide into a slurry formed by addition of major part of calcium cyanamide charge into water using constant stirring, maintaining alkaline pH at a temperature ranging between ambient to 80° C., stopping the addition of hydrogen sulphide, continuing the slow passing of carbon dioxide and addition of remaining part of calcium cyanamide charge and retaining the reaction mass to complete the secondary reactions to form the product for a period ranging from 2-5 hours and continuing passing of carbon dioxide at an increased rate for effecting decomposition of Ca(SH)2 for a period of 1.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: December 2, 2003
    Assignee: Council of Scientific and Industrial Research
    Inventors: Balakrishnan Srinivasa, Mahajan Shankar Shivram, Chaphekar Gopal Moreshwar, Gupte Milind Yeshwant, Kulkarni Mohan Parshuram, Bandarupalli Radha Krishna Murthy
  • Patent number: 6653505
    Abstract: 1-(3-methoxybenzyl)-3-substituted thiourea antioxidant compounds and improved lipids compositions which are supplemented with amounts of such antioxidant compounds effective for augmenting oxidative stability of the base lipid are provided. Also provided are methods for enhancing the oxidative stability of a lipid comprising supplementing a base lipid in need of enhanced oxidative stability with at least one 1-(3-methoxybenzyl)-3-substituted thiourea compound of the present invention.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: November 25, 2003
    Assignees: The United States of America as represented by the Secretary of Agriculture, The Fanning Corporation
    Inventors: Thomas P. Abbott, Alan Wohlman
  • Publication number: 20030215806
    Abstract: The present invention provides a method and reagent composition for attachment of target molecules onto the surface of a substrate, such as microwell plates, tubes, beads, microscope slides, silicon wafers or membranes. In one embodiment, the method and composition are used to immobilize nucleic acid probes onto plastic materials such as microwell plates, e.g., for use in hybridization assays. In a preferred embodiment, the method and composition are adapted for use with substantially flat surfaces, such as those provided by microscope slides and other plastic, silicon hydride, or organosilane-pretreated glass or silicone slide support surfaces. The reagent composition can then be used to attach a target molecule such as a biomolecule (e.g., a nucleic acid) which in turn can be used for specific binding reactions (e.g., to hybridize a nucleic acid to its complementary strand).
    Type: Application
    Filed: May 9, 2002
    Publication date: November 20, 2003
    Inventor: Mark A. Lewis
  • Publication number: 20030158442
    Abstract: A synthesis method which comprises reacting NH group-containing compounds with thiocyanates, cyanamides, nitrites or esters in the presence of a silylating agent to synthesize the corresponding nitrogen-containing addition or substitution products. This method not only enables the direct and efficient synthesis of nitrogen-containing compounds including isothioureas, guanidines, amidines and amides, but it also has a wide range of applications and is suitable for large-scale synthesis.
    Type: Application
    Filed: November 29, 2002
    Publication date: August 21, 2003
    Inventors: Takashi Emura, Tsuyoshi Haneishi
  • Patent number: 6608227
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: August 19, 2003
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: Dean A Wacker, John V Duncia, Joseph B Santella, III, Daniel S Gardner
  • Patent number: 6586628
    Abstract: 1-(3-methoxybenzyl)-3-substituted thiourea antioxidant compounds and improved lipids compositions which are supplemented with amounts of such antioxidant compounds effective for augmenting oxidative stability of the base lipid are provided. Also provided are methods for enhancing the oxidative stability of a lipid comprising supplementing a base lipid in need of enhanced oxidative stability with at least one 1-(3-methoxybenzyl)-3-substituted thiourea compound of the present invention.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: July 1, 2003
    Assignees: The United States of America, as represented by the Secretary of Agriculture, The Fanning Corporation
    Inventors: Thomas P. Abbott, Alan Wohlman
  • Patent number: 6545182
    Abstract: Methods and compositions for the treatment of pain using thiourea derivatives. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: April 8, 2003
    Assignee: Allergan Sales, Inc.
    Inventors: Ken Chow, Daniel W. Gil, Wenkui Fang, Michael E. Garst, Wheeler A. Larry
  • Patent number: 6545152
    Abstract: Novel chiral derivitaves of non-nucleoside inhibitors (NNI), particularly R-isomers of halopyridyl and thiazoyl thiourea compounds are provided as potent inhibitors of reverse transcriptase (RT), and particularly of retroviral RT, most particularly HIV RT. The stereospecific compounds and compositions of the invention inhibit replication of retrovirus, particularly human immunodeficiency virus-1 (HIV-1) and drug resistant strains.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: April 8, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Publication number: 20030060662
    Abstract: The present invention relates to an improved process for the preparation of thiourea. The object of the present invention is to provide an improved process for the preparation of Thiourea using Calcium Cyanamide, carbon dioxide and hydrogen sulphide. The process of the present invention comprises passing a mixture of Carbon dioxide ad hydrogen sulphide into a slurry formed by addition of major part of calcium cyanamide charge into water using constant stirring, maintaining alkaline pH at a temperature ranging between ambient to 80° C., stopping the addition of hydrogen sulphide, continuing the slow passing of carbon dioxide and addition of remaining part of calcium cyanamide charge and retaining the reaction mass to complete the secondary reactions to form the product for a period ranging from 2-5 hours and continuing passing of carbon dioxide at an increased rate for effecting decomposition of Ca(SH)2 for a period of 1.
    Type: Application
    Filed: March 24, 1998
    Publication date: March 27, 2003
    Inventors: BALAKRISHNAN SRINIVASA, MAHAJAN SHANKAR SHIVRAM, CHAPHEKAR GOPAL MORESHWAR, GUPTE MILIND YESHWANT, KULKARNI MOHAN PARSHURAM, BANDARUPALLI RADHA K MURTHY
  • Patent number: 6534542
    Abstract: Compounds of formula (i) and of formula (ii) wherein the symbols have the meaning disclosed in the specification, specifically or selectively modulate &agr;2B and/or &agr;2C adrenergic receptors in preference over &agr;2A adrenergic receptors, and as such are useful for alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: March 18, 2003
    Assignee: Allergen Sales, Inc.
    Inventors: Ken Chow, Daniel W. Gil, Wenkui Ken Fang, Michael E. Garst
  • Publication number: 20030040483
    Abstract: Compounds of peptide mimetic nature having the general formula I 1
    Type: Application
    Filed: March 23, 2000
    Publication date: February 27, 2003
    Inventors: Thomas Kruse Hansen, Bernd Peschke, Jesper Lau, Behrend Friedrich Lundt, Michael Ankersen, Brett Watson, Kjeld Madsen
  • Publication number: 20020183315
    Abstract: The present invention discloses compounds useful in treating or preventing IMPDH-associated disorders, such as transplant rejection and autoimmune diseases, having the formula (I), 1
    Type: Application
    Filed: May 23, 2002
    Publication date: December 5, 2002
    Inventors: Edwin J. Iwanowicz, Katerina Leftheris, Chunjian Liu, Toomas Mitt, Scott H. Watterson
  • Publication number: 20020165412
    Abstract: N-(Aryl)-2-arylethenesulfonamides and pharmaceutically acceptable salts and compositions thereof are useful as antiproliferative agents, including, for example, anticancer agents. They are also useful as radioprotective agents.
    Type: Application
    Filed: February 28, 2002
    Publication date: November 7, 2002
    Inventors: E. Premkumar Reddy, M.V. Ramana Reddy, Stanley C. Bell
  • Patent number: 6472430
    Abstract: Antiatherosclerotic compounds are provided which have the following structure: wherein R is lower alkyl; R1 is hydroxy, amino, or lower alkoxy, R2 and R3 are each independently hydrogen, alkyl or aryl; Ar is phenyl, indanyl, benzhydryl, or phenyl substituted with one or more member selected from the group consisting of halogen, lower alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aryloxy; or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: October 29, 2002
    Inventors: Hassan M. Elokdah, Theodore S. Sulkowski
  • Publication number: 20020045777
    Abstract: The present invention relates to aminocyclohexanol derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
    Type: Application
    Filed: August 9, 2001
    Publication date: April 18, 2002
    Inventors: Jean Ackermann, Johannes Aebi, Denise Blum, Alexander Chucholowski, Henrietta Dehmlow, Hans-Peter Maerki, Olivier Morand, Rene Trussardi, Elisabeth von der Mark, Sabine Wallbaum, Thomas Weller
  • Patent number: 6369073
    Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: April 9, 2002
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria Ornella Tinti, Piero Chiodi, Arduino Arduini
  • Patent number: 6335350
    Abstract: Compounds of the formula: are useful in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpesvirus.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: January 1, 2002
    Assignee: American Home Products Corporation
    Inventors: Jonathan Bloom, Martin DiGrandi, Russell Dushin, Stanley Lang, Bryan O'Hara
  • Patent number: 6316478
    Abstract: This invention relates to novel spiro compound derivatives of benzoisothiazolyl-urea and -thiourea and compositions thereof. These compounds are useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: November 13, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine L. Widdowson, Hong Nie
  • Patent number: 6307001
    Abstract: Hybrid electron donor compounds, suitable for use as adhesives or as components in adhesives, contain a carbon to carbon double bond attached to an aromatic ring and conjugated with the unsaturation in the aromatic ring and a vinyl ether moiety.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: October 23, 2001
    Assignee: National Starch and Chemical Investment Holding Corporation
    Inventor: Osama M. Musa
  • Patent number: 6300456
    Abstract: Compounds containing both electron donor and electron acceptor functionality are suitable for use in adhesives. The electron donor group is a carbon to carbon double bond attached to an aromatic ring and conjugated with the unsaturation in the ring. The electron acceptor group is a maleimide, acrylate, fumarate or maleate.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: October 9, 2001
    Assignee: National Starch and Chemical Investment Holding Corporation
    Inventor: Osama M. Musa
  • Patent number: RE40861
    Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: July 21, 2009
    Assignee: Sigma-Tau Industrie Farmaceutiche Reunite S.p.A.
    Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria O. Tinti, Piero Chiodi, Arduino Arduini